Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 6
1962 9
1963 4
1964 8
1965 10
1966 9
1967 6
1968 11
1969 9
1970 11
1971 5
1972 11
1973 9
1974 12
1975 17
1976 14
1977 12
1978 17
1979 16
1980 25
1981 27
1982 31
1983 39
1984 34
1985 30
1986 43
1987 51
1988 43
1989 50
1990 49
1991 58
1992 51
1993 49
1994 66
1995 87
1996 79
1997 71
1998 80
1999 90
2000 77
2001 82
2002 88
2003 78
2004 83
2005 87
2006 104
2007 92
2008 78
2009 95
2010 85
2011 108
2012 95
2013 94
2014 88
2015 86
2016 95
2017 83
2018 114
2019 132
2020 148
2021 174
2022 170
2023 135
2024 184
2025 173
2026 89

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,805 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: fukuda h. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.
Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Sekino Y, Tsutani Y, Nakajima R, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Nakamura K, Fukuda H, Watanabe SI; Japan Clinical Oncology Group; West Japan Oncology Group. Hattori A, et al. Among authors: fukuda h. Lancet Respir Med. 2024 Feb;12(2):105-116. doi: 10.1016/S2213-2600(23)00382-X. Epub 2024 Jan 3. Lancet Respir Med. 2024. PMID: 38184010 Clinical Trial.
Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
Nakagawa K, Watanabe SI, Wakabayashi M, Yotsukura M, Mimae T, Hattori A, Miyoshi T, Isaka M, Endo M, Yoshioka H, Tsutani Y, Isaka T, Maniwa T, Nakajima R, Suzuki K, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Sekino Y, Nakamura K, Fukuda H. Nakagawa K, et al. Among authors: fukuda h. J Thorac Oncol. 2025 Feb;20(2):157-166. doi: 10.1016/j.jtho.2024.10.002. Epub 2024 Oct 10. J Thorac Oncol. 2025. PMID: 39395662 Free article. Clinical Trial.
Local peptide signalling induces stomatal closure under drought stress.
Shimotohno A, Matsubayashi Y, Du Y, Senthilvadivel V, Suzuki T, Kato H, Kesherwani M, Kono M, Mishiro-Sato E, Kano K, Kojima M, Takebayashi Y, Sakakibara H, Soma F, Tama F, Hirota T, Torii KU, Yamaguchi-Shinozaki K, Fukuda H. Shimotohno A, et al. Among authors: fukuda h. Nat Commun. 2025 Dec 24;17(1):177. doi: 10.1038/s41467-025-66392-6. Nat Commun. 2025. PMID: 41444212 Free PMC article.
EML4-ALK Rearrangement Creates a Distinctive Myeloid Cell-Dominant Immunosuppressive Microenvironment in Lung Cancer.
Arai K, Nishito Y, Mizuno H, Motoi N, Hiraoka N, Fuse M, Arai Y, Shibata T, Sonobe Y, Kayukawa Y, Maruyama T, Fukuda H, Mizoguchi Y, Aikawa Y, Yoshida Y, Watanabe SI, Sakamoto H, Yamashita M, Kitano S, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Arai K, et al. Among authors: fukuda h. Cancer Immunol Res. 2025 Sep 2;13(9):1435-1452. doi: 10.1158/2326-6066.CIR-24-0532. Cancer Immunol Res. 2025. PMID: 40627846
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial.
Hiraga H, Machida R, Kawai A, Kunisada T, Yonemoto T, Endo M, Nishida Y, Nagano A, Ae K, Yoshida S, Asanuma K, Toguchida J, Furuta T, Nakayama R, Akisue T, Hiruma T, Morii T, Nishimura H, Hiraoka K, Takeyama M, Emori M, Tsukushi S, Hatano H, Kawashima H, Isu K, Tanaka K, Kataoka T, Fukuda H, Iwamoto Y, Ozaki T. Hiraga H, et al. Among authors: fukuda h. J Clin Oncol. 2025 Jun;43(16):1886-1897. doi: 10.1200/JCO-24-01281. Epub 2025 Mar 26. J Clin Oncol. 2025. PMID: 40138604 Free PMC article. Clinical Trial.
Genome sequencing provides high diagnostic yield and new etiological insights for intellectual disability and developmental delay.
Hamanaka K, Fujita A, Miyatake S, Misawa K, Koshimizu E, Uchiyama Y, Tsuchida N, Seyama R, Sakamoto M, Iwama K, Nishimura N, Utsuno Y, Fu L, Takizawa M, Liang Q, Itai T, Saida K, Ohori S, Kameyama S, Fukuda H, Hayashi Y, Inoue Y, Goto T, Ichikawa K, Kuki I, Fukuoka M, Kim K, Shiohama T, Shimoda K, Otsuka K, Ueda Y, Cho K, Yuge K, Tachi N, Yoshida M, Daida A, Hirasawa K, Yanagishita T, Yamamoto T, Shirai K, Mehr TF, Fattal-Valevski A, Lev D, Yokoyama H, Iwabuchi E, Saito Y, Miura M, Sugai K, Ishiyama A, Sasaki M, Watanabe Y, Takanashi JI, Kim CA, Yokochi K, Tohyama J, Mori T, Izumi Y, Hasegawa Y, Okamoto N, Ikeda T, Osaka H, Kawai Y, Omae Y, Tokunaga K, Kato M, Mizuguchi T, Matsumoto N. Hamanaka K, et al. Among authors: fukuda h. NPJ Genom Med. 2025 Aug 26;10(1):60. doi: 10.1038/s41525-025-00521-4. NPJ Genom Med. 2025. PMID: 40858643 Free PMC article.
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma.
Ishihara H, Omae K, Nemoto Y, Mizoguchi S, Katsurayama N, Nakayama T, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: fukuda h. Urol Oncol. 2025 Oct;43(10):598.e1-598.e10. doi: 10.1016/j.urolonc.2025.06.019. Epub 2025 Aug 5. Urol Oncol. 2025. PMID: 40754547
3,805 results